Saúde
The FDA approved Mounjaro for cardiovascular risk reduction, making it the first dual GIP/GLP-1 agonist with this indication. Here's what Brazilian patients should know about this milestone and what it means for future access.
Discover how semaglutide works on your brain to reduce food noise, cravings, and emotional eating through GLP-1 receptor pathways.
ANVISA recently flagged non-invasive glucose wearables as unreliable. We break down the science, the regulatory stance, and what this means for GLP-1 medication users tracking their blood sugar.
A Brazilian patient spent R$ 17,000 on Mounjaro for weight management and was denied reimbursement. Here's what the case reveals about GLP-1 coverage gaps in Brazil.
Research suggests GLP-1 medications may improve fertility outcomes in women with obesity and PCOS. Here's what the science says.
Wondering if your Brazilian health plan has to cover Ozempic or Mounjaro? Here is what the ANS rules actually determine about GLP-1 medication coverage and what patients can do.
